Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Will the Shingles Vaccine Market Evolve in Terms of Growth and Size by 2029?
The market size for the shingles vaccine has experienced swift growth in the recent years. The market, which was valued at $4.82 billion in 2024, is projected to reach $5.55 billion in 2025, indicating a compound annual growth rate (CAGR) of 15.0%. The significant expansion during the historic period can be associated with factors such as the growth in the elderly population, increased understanding of the benefits of vaccination, developments in healthcare infrastructure and immunization initiatives, a rise in immune-compromising conditions, and the elevated uptake of new and more efficient vaccines.
In the coming years, the shingles vaccine market is predicted to undergo a rapid expansion. With the size projected to escalate to $9.58 billion by 2029, it stands to reflect a compound annual growth rate (CAGR) of 14.6%. Various factors contribute to this growth in the forecast period, such as the increase in government refunds, favorable pricing strategies, growing rate of doctor recommendations, heightened prioritization of adult immunization in the public health sector, and increased global supply chain upgrades along with cold-chain capacity. During this forecast period, key trends to monitor include the progress in recombinant vaccine technology, advancements in systems of adjuvants, assimilation of shingles vaccines into adult immunization timetables, implementation of digital health platforms to track vaccines, and breakthroughs in vaccine formulation methods.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27413&type=smp
What factors are expected to fuel Shingles Vaccine market growth in the coming years?
The escalating tally of immunization programs is predicted to spur the expansion of the shingles vaccine market in the future. Immunization programs denote structured public health endeavors that methodically deliver vaccines to populace as a means to curb the transmission of communicable diseases. Due to the growing consciousness regarding preventive healthcare, more individuals are becoming inspired to get vaccinated, thus leading to an upsurge in the count of immunization programs. These programs boost the uptake of shingles vaccine by improving public cognizance and availability, rendering it optimal for elderly and susceptible groups. They mitigate the incidence of shingles and related complications via encouraging punctual and broad-based immunization, thereby enhancing the overall health of the community. For example, based on the data from the World Health Organization, in July 2025, a Switzerland-based Intergovernmental organization reported a hike in the coverage for the first dose of human papillomavirus (HPV) vaccine in girls, from 27% in 2023 to 31% in 2024. Therefore, the escalating tally of immunization programs is boosting the expansion of the shingles vaccine market.
What Are The Key Findings From The Segmentation Analysis Of The Shingles Vaccine Market?
The shingles vaccine market covered in this report is segmented
1) By Vaccine Type: Live Attenuated Vaccine, Recombinant Vaccine, Subunit Vaccine
2) By Product: Shingrix, Zostavax, Skyzoster
3) By Age Group: 50-59 Years, 60-69 Years, 70 Years And Above
4) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
5) By End User: Hospitals, Clinics, Pharmacies
Subsegments:
1) By Live Attenuated Vaccine: Virus Strain A, Virus Strain B, Virus Strain C
2) By Recombinant Vaccine: Recombinant Protein Vaccine, Recombinant Vector Vaccine, Recombinant Deoxyribonucleic Acid Vaccine
3) By Subunit Vaccine: Protein Subunit Vaccine, Polysaccharide Subunit Vaccine, Conjugate Subunit Vaccine
Which Trends Are Expected To Shape The Future Of The Shingles Vaccine Market?
Leading players in the shingles vaccine market are concentrating their efforts on creating revolutionary vaccine formulas like recombinant adjuvanted vaccines to improve the immune response and offer long-term defense against shingles. These recombinant adjuvanted vaccines employ synthetic viral proteins mixed with substances known as adjuvants to enhance the body’s immune response for superior conservation. In an instance, GlaxoSmithKline Pharmaceuticals Ltd., a pharmaceutical firm based in India, introduced a shingles vaccine named Shingrix in April 2023. Shingrix, a non-live, recombinant adjuvanted subunit vaccine, is applied intramuscularly in two doses to adults aged 50 or more to protect them from shingles (herpes zoster) and its accompanying complication, post-herpetic neuralgia. This highly potent vaccine guarantees over 90% defense against shingles, maintaining a robust immunity for a minimum of 10 years, even in geriatric and immunodeficient individuals.
What Are The Most Active Companies In The Shingles Vaccine Market Today?
Major companies operating in the shingles vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., GSK plc, Daiichi Sankyo Company Limited, Moderna Inc., Novavax Inc., Biological E. Limited., Serum Institute of India Pvt. Ltd., Dynavax Technologies Corporation, SK Bioscience Co. Ltd., CanSino Biologics Inc., Vaxart Inc., EuBiologics Co. Ltd., BCHT Biotech Co. Ltd., Green Cross Corp, Jiangsu Recbio Technology Co. Ltd., Curevo Inc., Inovio Pharmaceuticals Inc., POP Biotechnologies Inc.
Get The Full Report Here:
https://www.thebusinessresearchcompany.com/report/shingles-vaccine-global-market-report
Which Regional Markets Are Attracting The Most Investment In Shingles Vaccine?
North America was the largest region in the shingles vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingles vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=27413&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model